The Neubauer Lab

Category: Grants

  • Science Day Awards for the Moriggl Lab

    Vetmeduni Science Day 2022

    The following awards were awarded to members of the Moriggl lab on this year’s science day:

    • 2 poster awards were awarded to Marie Ploderer for her beautiful and informative poster on “Increased STAT5B levels lead to enhanced megakaryocytic differentiation correlating with thrombosis in myeloproliferative neoplasms”
    • 1 young researcher award was given to Heidi Neubauer for obtaining the highest amount of third party funding in the non-clinical area
    • 1 inventor award was awarded to Anna Orlova and Richard Moriggl for their patentable invention of novel STAT5 oligomerization inhibitors
    Best poster of the night designed by Marie Ploderer

    Congratulations to all awardees!

    https://entrepreneurial.vetmeduni.ac.at/vetmeduni-science-day-1-1

  • ERANET PerMed Video Competition

    Check out our submission for the ERANET_PerMed video competition summarizing 3 years of work with the JAKSTAT Target consortium.

    Video editing was done by MSc student Bilal Saqib from the Gunning Lab!

    https://erapermed.isciii.es/

  • FWF Stand-Alone Project funding awarded to Heidi Neubauer for research into disease mechanisms in MPN and thrombosis

    The Austrian Science Fund (FWF) has awarded funding to Heidi Neubauer to support her research on Myeloproliferative Neoplasms and thrombosis. This four year project will explore the role of the protein STAT5B in MPN disease mechanisms, where STAT5B could represent a novel prognostic marker and help explain patient phenotypes in these diseases. 

    Congrats Heidi for this incredible achievement. We are looking forward to some productive years of research.

    Read more about Heidi’s research here.

    Top left, Image of bone marrow section showing large platelet-producing megakaryocyte cells. Top right, peripheral blood smear stained to show red blood cells, white blood cells and platelets. Bottom, Section showing a blood clot (thrombosis) formed in the lung of a mouse with polycythemia vera (MPN).

  • Second funding period for Special Research Programme (SFB) F61 “Monarchies and Hierarchies in Shaping Chromatin Landscapes”, including Heidi Neubauer as new project leader

    The Special Research Programme (SFB) “Monarchies and Hierarchies in Shaping Chromatin Landscapes”, which commenced in 2017 and is coordinated by the University of Veterinary Medicine Vienna, has been extended for another four years (2021-2025). The consortium will continue with their recent successes to gain further insights into the role of the JAK-STAT signalling pathway in the development and treatment of infection, inflammation and cancer.

    Heidi Neubauer will also now join the SFB for the second funding period as a project leader, with Richard Moriggl as co-PI. The focus of this sub-project is to explore chromatin remodelling mediated by oncogenic STAT5 in T Cell Leukemia and Lymphoma.

    More information can be found here and here.

    Congratulations Heidi, Richard and the SFB network!

  • Heidi Neubauer is part of the ERA PerMed funded project “JAKSTAT-target”

    The project “Novel individualized therapies in JAK/STAT driven T cell malignancies” (Acronym: JAKSTAT-Target) aims to investigate the role of the JAK-STAT pathway in mature T cell lymphomas and to identify potential drugs and drug synergies targeting this pathway.

    The consortium of six research groups from Vienna (Heidi Neubauer), Helsinki (Satu Mustjoki, Tero Aittokallio), Cologne (Marco Herling) and Toronto (Patrick Gunning, Benjamin Haibe-Kains) will focus on the entities of T cell prolymphocytic leukemia (T-PLL) and T cell large granular lymphocyte leukemia (T-LGLL), both showing a high incidence of missense mutations in JAK-STAT pathway genes.

    The consortium, led by Satu Mustjoki, will uncover new mechanistic insights into these rare diseases and implement machine learning algorithms to predict synergistic effects from genomic, clinical and in vitro drug sensitivity data, ultimately integrating these data into clinical trials.

    For more details, please visit the JAK STAT Target Consortium website, the ERA Per Med Newsletter or the affiliated Twitter profile.

    March consortium meeting in Helsinki